Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma.

Bellut J, Bertz S, Nolte E, Stöhr C, Polifka I, Lieb V, Herrmann E, Jung R, Hartmann A, Wullich B, Taubert H, Wach S.

Sci Rep. 2017 Nov 27;7(1):16424. doi: 10.1038/s41598-017-16144-4.

2.

Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes.

Abbas HA, Bui NHB, Rajapakshe K, Wong J, Gunaratne P, Tsai KY, Coarfa C, Flores ER.

Cancer Res. 2018 Jan 15;78(2):451-462. doi: 10.1158/0008-5472.CAN-17-1803. Epub 2017 Nov 27.

PMID:
29180475
3.

Identifying biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co-expression network analysis.

He Z, Sun M, Ke Y, Lin R, Xiao Y, Zhou S, Zhao H, Wang Y, Zhou F, Zhou Y.

Oncotarget. 2017 Apr 25;8(17):27904-27914. doi: 10.18632/oncotarget.15842.

4.

Meta-analysis of gene expression and integrin-associated signaling pathways in papillary renal cell carcinoma subtypes.

Zhang K, Lee HM, Wei GH, Manninen A.

Oncotarget. 2016 Dec 20;7(51):84178-84189. doi: 10.18632/oncotarget.12390.

5.

Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas.

Haake SM, Weyandt JD, Rathmell WK.

Mol Cancer Res. 2016 Jul;14(7):589-98. doi: 10.1158/1541-7786.MCR-16-0115. Epub 2016 Jun 21. Review.

6.

Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms.

Yap NY, Rajandram R, Ng KL, Pailoor J, Fadzli A, Gobe GC.

Biomed Res Int. 2015;2015:476508. doi: 10.1155/2015/476508. Epub 2015 Sep 13. Review.

7.

Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.

Liu K, Ren Y, Pang L, Qi Y, Jia W, Tao L, Hu Z, Zhao J, Zhang H, Li L, Yue H, Han J, Liang W, Hu J, Zou H, Yuan X, Li F.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8311-35. eCollection 2015.

8.

An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways.

Wala SJ, Karamchandani JR, Saleeb R, Evans A, Ding Q, Ibrahim R, Jewett M, Pasic M, Finelli A, Pace K, Lianidou E, Yousef GM.

Mol Oncol. 2015 Oct;9(8):1667-77. doi: 10.1016/j.molonc.2015.04.007. Epub 2015 May 14.

9.

Identifying the determinants of response to MDM2 inhibition.

Saiki AY, Caenepeel S, Cosgrove E, Su C, Boedigheimer M, Oliner JD.

Oncotarget. 2015 Apr 10;6(10):7701-12.

10.

Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer.

Wei J, Costa C, Shen J, Yu L, Sanchez JJ, Qian X, Sun X, Zou Z, Gimenez-Capitan A, Yue G, Guan W, Rosell R, Liu B.

Br J Cancer. 2014 May 27;110(11):2662-8. doi: 10.1038/bjc.2014.231. Epub 2014 May 8.

11.

MRI phenotype in renal cancer: is it clinically relevant?

Campbell N, Rosenkrantz AB, Pedrosa I.

Top Magn Reson Imaging. 2014 Apr;23(2):95-115. doi: 10.1097/RMR.0000000000000019. Review.

12.

MicroRNA profiles classify papillary renal cell carcinoma subtypes.

Wach S, Nolte E, Theil A, Stöhr C, T Rau T, Hartmann A, Ekici A, Keck B, Taubert H, Wullich B.

Br J Cancer. 2013 Aug 6;109(3):714-22. doi: 10.1038/bjc.2013.313. Epub 2013 Jun 25.

13.

Renal cell carcinoma.

Cairns P.

Cancer Biomark. 2010;9(1-6):461-73. doi: 10.3233/CBM-2011-0176. Review.

14.

Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.

Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK, Tannir NM.

Hematol Oncol Clin North Am. 2011 Aug;25(4):853-69. doi: 10.1016/j.hoc.2011.05.003. Review.

15.

A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib.

Tuthill M, Barod R, Pyle L, Cook T, Chew S, Gore M, Maxwell P, Eisen T.

BMJ Case Rep. 2009;2009. pii: bcr08.2008.0732. doi: 10.1136/bcr.08.2008.0732. Epub 2009 Feb 16.

16.

A rapid and simple procedure for the establishment of human normal and cancer renal primary cell cultures from surgical specimens.

Valente MJ, Henrique R, Costa VL, Jerónimo C, Carvalho F, Bastos ML, de Pinho PG, Carvalho M.

PLoS One. 2011 May 4;6(5):e19337. doi: 10.1371/journal.pone.0019337.

17.

FXYD3: A Promising Biomarker for Urothelial Carcinoma.

Zhang Z, Pang ST, Kasper KA, Luan C, Wondergem B, Lin F, Chuang CK, Teh BT, Yang XJ.

Biomark Insights. 2011 Feb 15;6:17-26. doi: 10.4137/BMI.S6487.

18.

Papillary renal cell carcinoma with metastatic laparoscopic port site and vaginal involvement: a case report.

Chuang XE, Loh HL, Sim HG, Fong KL, Tan MH.

J Med Case Rep. 2011 Apr 1;5:131. doi: 10.1186/1752-1947-5-131.

19.

Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma.

Roos FC, Evans AJ, Brenner W, Wondergem B, Klomp J, Heir P, Roche O, Thomas C, Schimmel H, Furge KA, Teh BT, Thüroff JW, Hampel C, Ohh M.

Am J Pathol. 2011 Feb;178(2):853-60. doi: 10.1016/j.ajpath.2010.10.033.

20.

Isolation and characterization of progenitor-like cells from human renal proximal tubules.

Lindgren D, Boström AK, Nilsson K, Hansson J, Sjölund J, Möller C, Jirström K, Nilsson E, Landberg G, Axelson H, Johansson ME.

Am J Pathol. 2011 Feb;178(2):828-37. doi: 10.1016/j.ajpath.2010.10.026.

Supplemental Content

Support Center